Sowell Financial Services LLC Acquires 4,004 Shares of AstraZeneca Plc $AZN

Sowell Financial Services LLC purchased a new stake in AstraZeneca Plc (NYSE:AZN) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 4,004 shares of the company’s stock, valued at approximately $647,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Mascoma Wealth Management LLC bought a new position in shares of AstraZeneca during the 1st quarter worth about $26,000. Roxbury Financial LLC acquired a new stake in shares of AstraZeneca during the 2nd quarter worth approximately $29,000. Resources Management Corp CT ADV acquired a new stake in shares of AstraZeneca during the 1st quarter worth approximately $35,000. Allied Private Wealth LLC acquired a new stake in shares of AstraZeneca during the 2nd quarter worth approximately $35,000. Finally, GK Wealth Management LLC bought a new stake in shares of AstraZeneca during the third quarter valued at approximately $31,000. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Down 0.0%

Shares of AZN opened at $186.64 on Tuesday. The company has a market capitalization of $289.47 billion, a P/E ratio of 26.40, a PEG ratio of 1.31 and a beta of 0.27. AstraZeneca Plc has a one year low of $153.41 and a one year high of $212.71. The business’s 50 day simple moving average is $164.90 and its 200-day simple moving average is $180.18. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.89 and a quick ratio of 0.67.

AstraZeneca (NYSE:AZN) last released its quarterly earnings results on Friday, October 30th. The company reported $2.79 earnings per share for the quarter, beating analysts’ consensus estimates of $2.60 by $0.19. AstraZeneca had a return on equity of 31.45% and a net margin of 17.02%. The firm had revenue of $16.21 billion during the quarter, compared to analysts’ expectations of $16 billion. During the same period last year, the firm posted $2.38 EPS. The business’s revenue was up 6.5% on a year-over-year basis. As a group, sell-side analysts predict that AstraZeneca Plc will post 10.21 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on AZN shares. Wall Street Zen upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Saturday. CICC Research assumed coverage on shares of AstraZeneca in a research note on Sunday, August 23rd. They set an “outperform” rating and a $198.00 price target on the stock. Citigroup reissued a “buy” rating on shares of AstraZeneca in a report on Tuesday, October 6th. Royal Bank Of Canada assumed coverage on shares of AstraZeneca in a report on Tuesday, September 8th. They issued an “outperform” rating on the stock. Finally, Weiss Ratings upgraded shares of AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, October 26th. Sixteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, AstraZeneca presently has an average rating of “Moderate Buy” and a consensus target price of $206.67.

AstraZeneca Profile

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.